Hillenbrand Reports Fiscal First Quarter 2025 Results and Announces Sale of Majority Stake in Milacron Injection Molding and Extrusion Business
1. Hillenbrand sold 51% of Milacron for $287 million, aiming to pay down debt. 2. Revenue dropped 9% YoY, aligning with company expectations amid lower volumes. 3. Adjusted EPS fell by 19% to $0.56, signaling pressures from inflation and costs. 4. The annual guidance has been adjusted, reflecting impacts from the Milacron sale. 5. Hillenbrand is focusing on higher-growth markets, shifting from cyclical revenue streams.